In comparison with NSE and LDH performance at both early and intermediate stages of chemotherapy, the performance of cfDNA was most efficient to evaluate therapy response in NB patients (Tables 2, 3, 4, Figures 1, 2, 3, 4, 5). Here, ENO2 is linked to neuroblastoma.